Is PSG.DE stock a buy on this oversold bounce setup?

The setup is attractive for traders: entry near **€28.60–€29.00**, stop **€27.00**, targets **€31.00** and **€33.60**. Meyka AI grades PSG.DE B+ (BUY). This is not financial advice; size positions to risk limits and check upcoming company updates.

What are the main valuation metrics for PSG.DE stock?

Key metrics: price **€29.00**, EPS **€1.68**, trailing PE **17.26**, market cap **€333,862,500**, free cash flow yield **6.52%**, and current ratio **2.68**. These show solid cash flow and low leverage versus sector averages.

How does Meyka AI forecast affect the PSG.DE stock outlook?

Meyka AI's model projects a 5-year price of **€31.56** and a 7-year price of **€33.29**, implying modest upside. Forecasts guide outlook and are model-based projections, not guarantees, so use them with technical confirmation and risk controls.

What specific risks should traders watch for PSG.DE stock?

Watch inventory levels (days of inventory **400.36**) and dividend payout ratio above **100%**, which can pressure cash in bad quarters. Also monitor OTC sales trends and any distribution or regulatory news in Germany and EU markets.

DE Stocks

PSG.DE PharmaSGP (XETRA) €29.00 pre-market 18 Mar 2026: Oversold bounce, €33.60 target

ByDanny Kontos March 18, 2026March 18, 2026

PSG.DE stock trades at €29.00 pre-market on 18 Mar 2026 after a short dip to €28.60, creating an oversold bounce setup for active traders. Volume is elevated at 12,424 versus an average of 5,399, giving the move credibility. We examine the technical trigger, valuation metrics, and a practical price path to a near-term target around €33.60.